# US 2025/0084174 A1 · Therapeutic binding molecules

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0084174 A1
- Document ID: US20250084174A1
- Status: Published application
- Kind: A1
- Application number: 18/787,823
- Filed: 2024-07-29
- Published: 2025-03-13
- Earliest claimed: 2021-03-18
- Applicants: MedImmune Limited
- Inventors: Josquin NYS; Albert THOM; Peter CARIUK; Darren SCHOFIELD; Aidan RILEY; Catherine HUNTINGTON; David REES; Lorraine IRVING; Matthew ROBINSON
- Web page: https://patentgrep.com/patent/US20250084174A1

## CPC

- A61K 39/395: Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- C07K 16/2866: {against receptors for cytokines, lymphokines, interferons}
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/12: Antidiarrhoeals
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- G01N 33/6863: {Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors}
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 2039/505: {comprising antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/41: Glycosylation, sialylation, or fucosylation
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/72: Increased effector function due to an Fc-modification
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K 2317/77: Internalization into the cell
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- G01N 2333/7158: for chemokines
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The invention relates to binding molecules, such as antibodies, that bind to the chemokine receptor CCR9. More particularly, the invention relates to the treatment of CCR9-mediated diseases or conditions such as inflammatory bowel disease (IBD), and methods for the detection of CCR9, which make use of the binding molecules of the invention.

## Claims

### Claim 1

A method of treating a disease or condition in a subject, the method comprising administering to the subject an effective amount of a binding molecule that binds to CCR9 and comprises a heavy chain variable (VH) region having a set of CDRs HCDR1, HCDR2 and HCDR3 and a light chain variable (VL) region having a set of CDRs LCDR1, LCDR2 and LCDR3, wherein
(a) the VH region amino acid sequence comprises HCDR1 of SEQ ID NO: 1, HCDR2 of SEQ ID NO: 2 and HCDR3 of SEQ ID NO: 3, and wherein the VL region amino acid sequence comprises LCDR1 of SEQ ID NO: 4, LCDR2 of SEQ ID NO: 5 and LCDR3 of SEQ ID NO: 6;
(b) the VH region amino acid sequence comprises HCDR1 of SEQ ID NO: 7, HCDR2 of SEQ ID NO: 8 and HCDR3 of SEQ ID NO: 9, and wherein the VL region amino acid sequence comprises LCDR1 of SEQ ID NO: 10, LCDR2 of SEQ ID NO: 11 and LCDR3 of SEQ ID NO: 12; or
(c) the VH region amino acid sequence comprises HCDR1 of SEQ ID NO: 13, HCDR2 of SEQ ID NO: 14 and HCDR3 of SEQ ID NO: 15, and wherein the VL region amino acid sequence comprises LCDR1 of SEQ ID NO: 16, LCDR2 of SEQ ID NO: 17 and LCDR3 of SEQ ID NO: 18
or wherein any one or more of said HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 comprises 1, 2 or 3 amino acid substitutions compared to said sequences.

### Claim 2 (depends on 1)

The method of claim 1, wherein the VH region amino acid sequence comprises HCDR1 of SEQ ID NO: 1, HCDR2 of SEQ ID NO: 2 and HCDR3 of SEQ ID NO: 3, and wherein the VL region amino acid sequence comprises LCDR2 of SEQ ID NO: 5 and LCDR3 of SEQ ID NO: 6 and LCDR1 having an amino acid sequence selected from:
(a) SEQ ID NO: 4;
(b) SEQ ID NO: 19;
(c) SEQ ID NO: 20;
(d) SEQ ID NO: 21; and
(e) SEQ ID NO: 22.

### Claim 3 (depends on 1)

The method of claim 1, wherein:
(i) the VH region amino acid sequence comprises SEQ ID NO: 51, or a sequence having at least 80%, 85%, 90%, 95%, 98% or 99% sequence identity thereto and; the VL region amino acid sequence comprises SEQ ID NO: 52, or a sequence having at least 80%, 85%, 90%, 95%, 98% or 99% sequence identity thereto;
(ii) the VH region amino acid sequence comprises SEQ ID NO: 51, or a sequence having at least 80%, 85%, 90%, 95%, 98% or 99% sequence identity thereto and; the VL region amino acid sequence comprises SEQ ID NO: 53, or a sequence having at least 80%, 85%, 90%, 95%, 98% or 99% sequence identity thereto;
(iii) the VH region amino acid sequence comprises SEQ ID NO: 51, or a sequence having at least 80%, 85%, 90%, 95%, 98% or 99% sequence identity thereto and; the VL region amino acid sequence comprises SEQ ID NO: 54, or a sequence having at least 80%, 85%, 90%, 95%, 98% or 99% sequence identity thereto;
(iv) the VH region amino acid sequence comprises SEQ ID NO: 51, or a sequence having at least 80%, 85%, 90%, 95%, 98% or 99% sequence identity thereto; and the VL region amino acid sequence comprises SEQ ID NO: 55; or a sequence having at least 80%, 85%, 90%, 95%, 98% or 99% sequence identity thereto; or
(v) the VH region amino acid sequence comprises SEQ ID NO: 56, or a sequence having at least 80%, 85%, 90%, 95%, 98% or 99% sequence identity thereto and; the VL region amino acid sequence comprises SEQ ID NO: 57, or a sequence having at least 80%, 85%, 90%, 95%, 98% or 99% sequence identity thereto.

### Claim 4 (depends on 1)

The method of claim 1, wherein the binding molecule is an anti-CCR9 antibody, or an antigen-binding fragment thereof, optionally wherein the anti-CCR9 antibody, or antigen-binding fragment thereof is humanised, chimeric, or fully human.

### Claim 5 (depends on 4)

The method of claim 4, wherein the immunoglobulin Fc domain or fragment:
(a) is an IgG Fc domain or fragment thereof;
(b) is a human IgG Fc domain or fragment thereof;
(c) is a human IgG1 Fc domain or fragment thereof;
(d) is modified compared to the corresponding wild-type Fc domain, wherein said modification leads to an increased affinity for one or more Fcγ receptors;
(e) is modified compared to the corresponding wild-type Fc domain, wherein said modification leads to an enhanced antibody dependent cell-mediated cytotoxicity response; and/or
(f) comprises an afucosylated N-linked glycan at amino acid position 297.

### Claim 6 (depends on 1)

The method of claim 1, wherein the binding molecule is:
(a) afucosylated;
(b) afucosylated at amino acid position 297; or
(c) present in a composition comprising multiple copies of said binding molecule, wherein at least 50%, 75%, 80%, 90%, 95%, 98%, 99% or 100% of the copies of the binding molecule in the composition are afucosylated.

### Claim 7 (depends on 1)

The method of claim 1, wherein the binding molecule:
(a) binds to human CCR9;
(b) binds to human CCR9A and human CCR9B;
(c) binds to cynomolgus CCR9; and/or
(e) does not bind to CCR5, CCR8, CXCR1 or CXCR2.

### Claim 8 (depends on 1)

The method of claim 1, wherein the binding molecule:
(a) is capable of mediating antibody dependent cell-mediated cytotoxicity against a CCR9-expressing cell to which it binds;
(b) is capable of mediating antibody dependent cell-mediated cytotoxicity against a CCR9-expressing lymphocyte to which it binds;
(c) can be bound by an FcγR;
(d) can be bound by FcγRIIIa;
(e) is capable of cross-linking an immune effector cell to a CCR9-expressing cell;
(f) is capable of cross-linking an immune effector cell to a CCR9-expressing cell and activating antibody dependent cell-mediated cytotoxicity by the effector cell;
(g) is capable of inhibiting CCL25 induced CCR9 receptor internalisation;
(h) is capable of inhibiting CCL25 mediated migration of CCR9 expressing T cells to the gut,
(i) is capable of cross-linking an immune effector cell to a CCR9-expressing cell and activating antibody dependent cell-mediated cytotoxicity by the effector cell, thereby causing lysis of the CCR9-expressing cell; and/or
(j) is capable of depleting CCR9-expressing cells in a population of cells comprising CCR9-expressing cells and immune effector cells.

### Claim 9 (depends on 1)

The method of claim 1, wherein the binding molecule is capable of binding to human CCR9 with an affinity (KD) of about 0.1 nM, optionally 0.09 nM.

### Claim 10 (depends on 1)

The method of claim 1, wherein the disease is a CCR9-medicated disease, or wherein the disease is mediated by CCR9 expressing cells.

### Claim 11 (depends on 1)

The method of claim 1, wherein the disease is selected from the group consisting of inflammatory bowel disease, Crohn's disease, ileal/ileocolonic Crohn's disease, ulcerative colitis, T-cell acute lymphoblastic leukaemia, prostate cancer, breast cancer, melanoma, circulating cells from a solid tumour, liver fibrosis and acute liver inflammation.

### Claim 12 (depends on 1)

The method of claim 1, wherein the disease is selected from the group consisting of T-cell acute lymphoblastic leukaemia, prostate cancer, breast cancer, melanoma, circulating cells from a solid tumour, liver fibrosis and acute liver inflammation.

### Claim 13

A method of treating an inflammatory bowel disease in a subject, the method comprising administering to the subject an effective amount of a binding molecule that binds to CCR9 and comprises a heavy chain variable (VH) region having a set of CDRs HCDR1, HCDR2 and HCDR3 and a light chain variable (VL) region having a set of CDRs LCDR1, LCDR2 and LCDR3, wherein
(a) the VH region amino acid sequence comprises HCDR1 of SEQ ID NO: 1, HCDR2 of SEQ ID NO: 2 and HCDR3 of SEQ ID NO: 3, and wherein the VL region amino acid sequence comprises LCDR1 of SEQ ID NO: 4, LCDR2 of SEQ ID NO: 5 and LCDR3 of SEQ ID NO: 6;
(b) the VH region amino acid sequence comprises HCDR1 of SEQ ID NO: 7, HCDR2 of SEQ ID NO: 8 and HCDR3 of SEQ ID NO: 9, and wherein the VL region amino acid sequence comprises LCDR1 of SEQ ID NO: 10, LCDR2 of SEQ ID NO: 11 and LCDR3 of SEQ ID NO: 12; or
(c) the VH region amino acid sequence comprises HCDR1 of SEQ ID NO: 13, HCDR2 of SEQ ID NO: 14 and HCDR3 of SEQ ID NO: 15, and wherein the VL region amino acid sequence comprises LCDR1 of SEQ ID NO: 16, LCDR2 of SEQ ID NO: 17 and LCDR3 of SEQ ID NO: 18 or wherein any one or more of said HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 comprises 1, 2 or 3 amino acid substitutions compared to said sequences.

### Claim 14 (depends on 13)

The method of claim 13, wherein the disease is selected from the group consisting of inflammatory bowel disease, Crohn's disease, ileal/ileocolonic Crohn's disease, ulcerative colitis, T-cell acute lymphoblastic leukaemia, prostate cancer, breast cancer, melanoma, circulating cells from a solid tumour, liver fibrosis and acute liver inflammation.

### Claim 15 (depends on 13)

The method of claim 13, wherein the VH region amino acid sequence comprises HCDR1 of SEQ ID NO: 1, HCDR2 of SEQ ID NO: 2 and HCDR3 of SEQ ID NO: 3, and wherein the VL region amino acid sequence comprises LCDR2 of SEQ ID NO: 5 and LCDR3 of SEQ ID NO: 6 and LCDR1 having an amino acid sequence selected from:
(a) SEQ ID NO: 4;
(b) SEQ ID NO: 19;
(c) SEQ ID NO: 20;
(d) SEQ ID NO: 21; and
(e) SEQ ID NO: 22.

### Claim 16

A method of treating a disease or condition in a subject, the method comprising administering to the subject an effective amount of a binding molecule which binds to CCR9, wherein:
(a) said binding molecule is capable of mediating antibody dependent cell-mediated cytotoxicity against a CCR9-expressing cell to which it binds
(b) binding of the binding molecule to CCR9 does not induce internalisation of CCR9, and/or
(c) the binding molecule competes with CC25 binding to CCR9, optionally human CCR9, optionally human CCR9A and CCR9B.

### Claim 17 (depends on 16)

The method of claim 16, wherein the disease is a CCR9-medicated disease, or wherein the disease is mediated by CCR9 expressing cells.

### Claim 18 (depends on 16)

The method of claim 16, wherein the binding molecule which binds to CCR9 comprises a heavy chain variable (VH) region having a set of CDRs HCDR1, HCDR2 and HCDR3 and a light chain variable (VL) region having a set of CDRs LCDR1, LCDR2 and LCDR3, wherein
(a) the VH region amino acid sequence comprises HCDR1 of SEQ ID NO: 1, HCDR2 of SEQ ID NO: 2 and HCDR3 of SEQ ID NO: 3, and wherein the VL region amino acid sequence comprises LCDR1 of SEQ ID NO: 4, LCDR2 of SEQ ID NO: 5 and LCDR3 of SEQ ID NO: 6;
(b) the VH region amino acid sequence comprises HCDR1 of SEQ ID NO: 7, HCDR2 of SEQ ID NO: 8 and HCDR3 of SEQ ID NO: 9, and wherein the VL region amino acid sequence comprises LCDR1 of SEQ ID NO: 10, LCDR2 of SEQ ID NO: 11 and LCDR3 of SEQ ID NO: 12; or
(c) the VH region amino acid sequence comprises HCDR1 of SEQ ID NO: 13, HCDR2 of SEQ ID NO: 14 and HCDR3 of SEQ ID NO: 15, and wherein the VL region amino acid sequence comprises LCDR1 of SEQ ID NO: 16, LCDR2 of SEQ ID NO: 17 and LCDR3 of SEQ ID NO: 18 or wherein any one or more of said HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 comprises 1, 2 or 3 amino acid substitutions compared to said sequences.
